S&P 500   5,258.04 (+0.18%)
DOW   39,823.15 (+0.16%)
QQQ   444.94 (+0.02%)
AAPL   172.11 (-0.69%)
MSFT   421.38 (-0.01%)
META   488.49 (-1.09%)
GOOGL   151.13 (+0.17%)
AMZN   180.58 (+0.42%)
TSLA   175.50 (-2.41%)
NVDA   903.95 (+0.16%)
NIO   4.50 (-3.64%)
AMD   180.16 (+0.32%)
BABA   72.39 (+1.12%)
T   17.67 (+0.68%)
F   13.25 (+1.45%)
MU   117.73 (-1.18%)
CGC   8.49 (-11.10%)
GE   175.94 (-2.32%)
DIS   122.48 (+1.24%)
AMC   3.73 (-14.06%)
PFE   27.84 (+0.22%)
PYPL   66.99 (+0.63%)
XOM   116.31 (+1.17%)
S&P 500   5,258.04 (+0.18%)
DOW   39,823.15 (+0.16%)
QQQ   444.94 (+0.02%)
AAPL   172.11 (-0.69%)
MSFT   421.38 (-0.01%)
META   488.49 (-1.09%)
GOOGL   151.13 (+0.17%)
AMZN   180.58 (+0.42%)
TSLA   175.50 (-2.41%)
NVDA   903.95 (+0.16%)
NIO   4.50 (-3.64%)
AMD   180.16 (+0.32%)
BABA   72.39 (+1.12%)
T   17.67 (+0.68%)
F   13.25 (+1.45%)
MU   117.73 (-1.18%)
CGC   8.49 (-11.10%)
GE   175.94 (-2.32%)
DIS   122.48 (+1.24%)
AMC   3.73 (-14.06%)
PFE   27.84 (+0.22%)
PYPL   66.99 (+0.63%)
XOM   116.31 (+1.17%)
S&P 500   5,258.04 (+0.18%)
DOW   39,823.15 (+0.16%)
QQQ   444.94 (+0.02%)
AAPL   172.11 (-0.69%)
MSFT   421.38 (-0.01%)
META   488.49 (-1.09%)
GOOGL   151.13 (+0.17%)
AMZN   180.58 (+0.42%)
TSLA   175.50 (-2.41%)
NVDA   903.95 (+0.16%)
NIO   4.50 (-3.64%)
AMD   180.16 (+0.32%)
BABA   72.39 (+1.12%)
T   17.67 (+0.68%)
F   13.25 (+1.45%)
MU   117.73 (-1.18%)
CGC   8.49 (-11.10%)
GE   175.94 (-2.32%)
DIS   122.48 (+1.24%)
AMC   3.73 (-14.06%)
PFE   27.84 (+0.22%)
PYPL   66.99 (+0.63%)
XOM   116.31 (+1.17%)
S&P 500   5,258.04 (+0.18%)
DOW   39,823.15 (+0.16%)
QQQ   444.94 (+0.02%)
AAPL   172.11 (-0.69%)
MSFT   421.38 (-0.01%)
META   488.49 (-1.09%)
GOOGL   151.13 (+0.17%)
AMZN   180.58 (+0.42%)
TSLA   175.50 (-2.41%)
NVDA   903.95 (+0.16%)
NIO   4.50 (-3.64%)
AMD   180.16 (+0.32%)
BABA   72.39 (+1.12%)
T   17.67 (+0.68%)
F   13.25 (+1.45%)
MU   117.73 (-1.18%)
CGC   8.49 (-11.10%)
GE   175.94 (-2.32%)
DIS   122.48 (+1.24%)
AMC   3.73 (-14.06%)
PFE   27.84 (+0.22%)
PYPL   66.99 (+0.63%)
XOM   116.31 (+1.17%)
NASDAQ:ONVO

Organovo (ONVO) Stock Price, News & Analysis

$1.03
+0.03 (+2.48%)
(As of 03:29 PM ET)
Today's Range
$1.01
$1.05
50-Day Range
$0.90
$1.12
52-Week Range
$0.89
$2.31
Volume
37,649 shs
Average Volume
125,060 shs
Market Capitalization
$10.39 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Organovo MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
1.35% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.47mentions of Organovo in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.74) to ($1.41) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.88 out of 5 stars

Medical Sector

831st out of 939 stocks

Biological Products, Except Diagnostic Industry

140th out of 154 stocks

ONVO stock logo

About Organovo Stock (NASDAQ:ONVO)

Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments. The company was incorporated in 2007 and is headquartered in San Diego, California.

ONVO Stock Price History

ONVO Stock News Headlines

AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
Organovo Holdings Inc ONVO
ONVO Continues Progress
Organovo: Fiscal Q3 Earnings Snapshot
AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
ONVO, FATH and BYU among mid-day movers
ONVO Organovo Holdings, Inc.
Organovo (NASDAQ: ONVO)
See More Headlines
Receive ONVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Organovo and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/08/2024
Today
3/28/2024
Fiscal Year End
3/31/2024
Next Earnings (Estimated)
7/11/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:ONVO
Fax
N/A
Employees
15
Year Founded
N/A

Profitability

Net Income
$-17,260,000.00
Net Margins
-4,061.12%
Pretax Margin
-7,885.54%

Debt

Sales & Book Value

Annual Sales
$370,000.00
Book Value
$1.76 per share

Miscellaneous

Free Float
9,638,000
Market Cap
$10.14 million
Optionable
Optionable
Beta
0.90
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Mr. Keith E. Murphy (Age 52)
    Company Secretary & Executive Chairman
    Comp: $626.24k
  • Ms. Vaidehi Joshi (Age 38)
    Director of Discovery Biology & Director
    Comp: $91.4k
  • Mr. Thomas P. Hess CPA (Age 60)
    MBA, President & CFO
  • Dr. Curtis M. Tyree Ph.D.
    Senior Vice President of Strategy & Business Development

ONVO Stock Analysis - Frequently Asked Questions

How have ONVO shares performed in 2024?

Organovo's stock was trading at $1.11 on January 1st, 2024. Since then, ONVO shares have decreased by 6.3% and is now trading at $1.0401.
View the best growth stocks for 2024 here
.

When is Organovo's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, July 11th 2024.
View our ONVO earnings forecast
.

How were Organovo's earnings last quarter?

Organovo Holdings, Inc. (NASDAQ:ONVO) released its quarterly earnings data on Thursday, February, 8th. The medical research company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.01. The medical research company had revenue of $0.01 million for the quarter, compared to analysts' expectations of $0.08 million. Organovo had a negative trailing twelve-month return on equity of 182.88% and a negative net margin of 4,061.12%.

When did Organovo's stock split?

Organovo shares reverse split on Wednesday, August 19th 2020. The 1-20 reverse split was announced on Monday, August 17th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, August 18th 2020. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What is Taylor Crouch's approval rating as Organovo's CEO?

3 employees have rated Organovo Chief Executive Officer Taylor Crouch on Glassdoor.com. Taylor Crouch has an approval rating of 38% among the company's employees. This puts Taylor Crouch in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Organovo own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Organovo investors own include Brainstorm Cell Therapeutics (BCLI), NVIDIA (NVDA), Aerojet Rocketdyne (AJRD), Blackstone (BX), LADENBURG THALM/SH SH (LTS), Advanced Micro Devices (AMD), Exelixis (EXEL), Micron Technology (MU), Novavax (NVAX) and OPKO Health (OPK).

Who are Organovo's major shareholders?

Organovo's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (3.52%), Vanguard Group Inc. (3.52%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include David Gobel and Douglas Jay Cohen.
View institutional ownership trends
.

How do I buy shares of Organovo?

Shares of ONVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ONVO) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners